Faron Pharmaceuticals Oy

("Faron" or the "Company")

Updated corporate presentation

Company announcement, 22 June 2021 at 9.00 AM (EEST)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, has today published an updated corporate presentation on its website.

The presentation contains previously published Company information, views of Management and data from Faron's development programmes.

Faron Pharmaceuticals Oy

("Faron" or the "Company")

First-in-human bexmarilimab results published in Clinical Cancer Research

- Results reveal the role of Clever-1 receptor in supressing adaptive immunity

- Bexmarilimab's macrophage-targeting approach activates T-cells and drives anti-tumour immune responses in cold tumours that are not otherwise responsive to immunotherapy

Company announcement, 3 June 2021 at 9.00 AM (EET)
 

 Faron Pharmaceuticals Oy

("Faron" or the "Company")

TR-1: Standard form for notification of major holdings

[][][][][][][][]
NOTIFICATION OF
MAJOR HOLDINGS
(to
be sent to the
relevant issuer
and
to the FCA in
Microsoft Word
format
if possible)[i]